At page 44, line 34, please rewrite "K3Fe(CN)6," as --K₃Fe(CN)₆,--.

At page 44, line 34, please rewrite "5mMK4Fe(CN)6" as --5 mM K₄Fe(CN)₆--.

In the Claims:

- 11. A method for producing cells for implantation at the site of a bone infirmity in a human, said method comprising the steps of:
 - (a) transforming a <u>cultured</u> human progenitor cell <u>or a bone marrow stromal</u>
 <u>cell</u> with a DNA encoding bone morphogenesis protein 2 (BMP-2); and
 - (b) culturing the <u>cultured</u> human progenitor cell <u>or bone marrow stromal cell</u> transformed in step (a),

whereby cells are produced for implantation at the site of a bone infirmity in a human.

Please cancel claim 13 without prejudice.

- 14. The method of claim [13] 11 wherein said human progenitor cell is a bone marrow stromal cultured cell line cell.
- 15. The method of claim[13] 1 wherein said cell contains an endogenous bone morphogenesis protein receptor.
- 17. A method for producing cells for implantation at the site of a bone infirmity in a human, said method comprising the steps of:

- (a) transforming a <u>cultured</u> human progenitor cell <u>or a bone marrow stromal</u>

 <u>cell</u> with a DNA encoding bone morphogenesis protein 2 and a DNA

 encoding a bone morphogenesis protein receptor protein; and
- (b) culturing the human progenitor cell transformed in step (a),

whereby a cell for implantation at the site of a bone infirmity is produced.

Please cancel claim 18 without prejudice.

- 19. The method of claim [18] <u>17</u> wherein said human progenitor cell is a pluripotent progenitor stem cell.
- 20. The method of claim [18] <u>17</u> wherein said human progenitor stem cell contains an endogenous bone morphogenesis protein receptor.

REMARKS

With the entry of the present amendment, claims 11-12, 14-17 and 19-23 are in this application. Claims 11, 14-15, 17 and 19-20 been amended for proper antecedent basis and to better claim the invention. None of the amendments made herein constitute the addition of new matter.

The Objection to the Specification

The Examiner has requested that the Specification be amended to provide generic language related to such trademarked items as "RNAZOL". Applicants have endeavored to comply with the request of the Examiner.